Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer.

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E.

Cancer Causes Control. 2004 Apr;15(3):255-65.

PMID:
15090720
2.

Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum.

Platz EA, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1059-65.

3.

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J.

PLoS Med. 2007 Mar;4(3):e103.

4.

Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.

Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1262-9.

5.

Serum vitamin D concentration and prostate cancer risk: a nested case-control study.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team.

J Natl Cancer Inst. 2008 Jun 4;100(11):796-804. doi: 10.1093/jnci/djn152. Epub 2008 May 27.

6.

Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.

Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):121-6.

7.

Calcium and fructose intake in relation to risk of prostate cancer.

Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC.

Cancer Res. 1998 Feb 1;58(3):442-7.

8.

Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort.

McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE.

Breast Cancer Res. 2009;11(4):R64. doi: 10.1186/bcr2356. Epub 2009 Aug 28.

9.

Plasma vitamin D metabolites and risk of colorectal cancer in women.

Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, Giovannucci EL.

Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1502-8.

10.

A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer.

Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL.

J Natl Cancer Inst. 2007 Jul 18;99(14):1120-9. Epub 2007 Jul 10.

11.

Prospective study of sex hormone levels and risk of prostate cancer.

Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ.

J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26.

12.

A prospective study of calcium intake and incident and fatal prostate cancer.

Giovannucci E, Liu Y, Stampfer MJ, Willett WC.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):203-10.

13.

Pre-diagnostic plasma 25-hydroxyvitamin D levels and risk of non-melanoma skin cancer in women.

Liang G, Nan H, Qureshi AA, Han J.

PLoS One. 2012;7(4):e35211. doi: 10.1371/journal.pone.0035211. Epub 2012 Apr 6.

14.

Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.

Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ.

Cancer Res. 1999 Mar 15;59(6):1225-30.

15.

Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women.

Fedirko V, Torres-Mejía G, Ortega-Olvera C, Biessy C, Angeles-Llerenas A, Lazcano-Ponce E, Saldaña-Quiroz VA, Romieu I.

Cancer Causes Control. 2012 Jul;23(7):1149-62. doi: 10.1007/s10552-012-9984-z. Epub 2012 May 24.

PMID:
22622862
16.

Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.

Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):783-8.

17.

Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer.

Jacobs ET, Giuliano AR, Martínez ME, Hollis BW, Reid ME, Marshall JR.

J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):533-7.

PMID:
15225833
18.

Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.

Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Causes Control. 2005 Apr;16(3):255-62.

PMID:
15947877
19.

Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort.

Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN.

Eur J Cancer. 2010 Mar;46(5):932-6. doi: 10.1016/j.ejca.2009.12.030. Epub 2010 Feb 8.

20.

Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Taylor EN, Hoofnagle AN, Curhan GC.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):667-75. doi: 10.2215/CJN.07060714. Epub 2015 Jan 26.

Items per page

Supplemental Content

Write to the Help Desk